| Members |
targetComponentId |
| Gland contrast radiography NOS |
Plain X-ray of gland with contrast (procedure) |
| Gland contrast radiography NOS |
Plain X-ray of gland with contrast (procedure) |
| glandulær intraepitelial neoplasi, grad III |
High grade glandular intraepithelial neoplasia |
| Glass fragment, device |
Glass fragment (physical object) |
| Glass worker NOS |
Glass worker |
| Glass worker NOS |
Glass worker |
| glaukom associeret med sygdomme i linsen, ikke nærmere specificeret |
Phacogenic glaucoma |
| glaukom associeret med øjeninflammation |
Glaucoma due to eye inflammation (disorder) |
| Glaukom forårsaget af silikoneolie |
Glaucoma caused by silicone oil |
| glaukom efter kirurgi |
Open angle glaucoma due to ocular surgery (disorder) |
| mistanke om glaukom |
At least 1 of these in 1 eye: optic nerve or nerve fibre layer suggestive of glaucoma; abnormal visual field consistent with glaucoma; an elevated IOP > 22 mm Hg. |
| Gliding bacteria |
Non-photosynthetic, non-fruiting gliding bacteria |
| glioblastom iht. kategori |
Glioblastoma |
| glioblastom |
Glioblastoma |
| glipizid 10 mg tablet med modificeret udløsning |
Product containing only glipizide in oral dose form (medicinal product form) |
| Glipizide 10mg prolonged-release oral tablet |
Product containing only glipizide in oral dose form (medicinal product form) |
| glipizid 2,5 mg tablet med modificeret udløsning |
Product containing only glipizide in oral dose form (medicinal product form) |
| Glipizide 2.5mg prolonged-release oral tablet |
Product containing only glipizide in oral dose form (medicinal product form) |
| glipizid 5 mg tablet med modificeret udløsning |
Product containing only glipizide in oral dose form (medicinal product form) |
| Glipizide 5mg prolonged-release oral tablet |
Product containing only glipizide in oral dose form (medicinal product form) |
| globus abdominalis |
Functional bloating (disorder) |
| glomus jugulare-tumor |
Malignant glomus jugulare tumor |
| Glomus neoplasm of mastoid |
Benign glomus tumor of mastoid |
| glomustumor |
Benign glomus tumour |
| glomustumor |
Benign glomus tumour |
| glomustumor i øre |
Benign glomus tumor of ear (disorder) |
| Glomustumor i huden |
Benign glomus tumor of skin |
| Glomus tumour |
Benign glomus tumour |
| glomus vagale-tumor |
Malignant vagal paraganglioma (disorder) |
| fund vedr. glottis udtrykt ved TNM-systemet |
American Joint Committee on Cancer allowable value |
| Glukagonom |
Malignant glucagonoma of pancreas (disorder) |
| Glucagonoma |
Glucagonoma, malignant |
| Glucagonoma of uncertain behavior |
Malignant glucagonoma of pancreas (disorder) |
| glukagonom |
Glucagonoma, malignant |
| Gluconobacter oxydans subspecies industrius |
Gluconobacter oxydans (organism) |
| Gluconobacter oxydans subspecies melanogenes |
Gluconobacter oxydans (organism) |
| Gluconobacter oxydans subspecies oxydans |
Gluconobacter oxydans (organism) |
| Gluconobacter oxydans subspecies sphaericus |
Gluconobacter oxydans (organism) |
| Gluconobacter oxydans subspecies suboxydans |
Gluconobacter oxydans (organism) |
| glucose 10 % infusionsvæske, opløsning, flaske |
Product containing precisely glucose 200 milligram/1 milliliter conventional release solution for injection (clinical drug) |
| glucose 15 % infusionsvæske, opløsning i flaske |
Product containing precisely glucose 150 milligram/1 milliliter conventional release solution for injection (clinical drug) |
| glucose 20 % infusionsvæske opløsning polyætylenflaske a 500 ml |
Product containing precisely glucose 200 milligram/1 milliliter conventional release solution for injection (clinical drug) |
| glucose 20 % infusionsvæske, opløsning i flaske |
Product containing precisely glucose 200 milligram/1 milliliter conventional release solution for injection (clinical drug) |
| glucose 40 % infusionsvæske, opløsning i flaske |
Glucose 400 mg/mL solution for injection |
| glucose 50 % infusionsvæske, opløsning i flaske |
Product containing precisely glucose 200 milligram/1 milliliter conventional release solution for injection (clinical drug) |
| glucose 50 % injektionsvæske, opløsning i fyldt injektionssprøjte |
Product containing precisely glucose 200 milligram/1 milliliter conventional release solution for injection (clinical drug) |
| glucose 70 % infusionsvæske, opløsning i pose |
Product containing precisely glucose 200 milligram/1 milliliter conventional release solution for injection (clinical drug) |
| glucose i prøve |
Glucose level - finding |
| Glucose tolerance test NOS |
Measurement of blood glucose in the fasting state and at specific intervals before and after oral or intravenous glucose load to determine the ability to maintain homeostasis of glucose. |
| Glucose tolerance test NOS |
Measurement of blood glucose in the fasting state and at specific intervals before and after oral or intravenous glucose load to determine the ability to maintain homeostasis of glucose. |
| Gluma - Dentine bonding agent |
Dentine bonding agent |
| Gluphosphate causing toxic effect |
Glyphosate toxicity |
| Glycerin 10% conventional release eye drops |
Glycerol 10 mg/mL eye solution |
| glycerin 10 % øjendråber uden konserveringsmiddel |
Glycerol 10 mg/mL eye solution |
| Glycerin 20% conventional release eye drops |
Product containing only glycerol in ocular dose form (medicinal product form) |
| glycerin 20 % øjendråber uden konserveringsmiddel |
Product containing only glycerol in ocular dose form (medicinal product form) |
| Glycerin 30% conventional release eye drops |
Product containing only glycerol in ocular dose form (medicinal product form) |
| glycerin 30 % øjendråber uden konserveringsmiddel |
Product containing only glycerol in ocular dose form (medicinal product form) |
| Glycerin 50% conventional release eye drops |
Glycerol 500 mg/mL eye solution |
| glycerin 50 % øjendråber uden konserveringsmiddel |
Glycerol 500 mg/mL eye solution |
| glycerin 50 % opløsning |
Glycerol only product |
| glycerol suppositorium a 1 g til spædbørn |
Product containing precisely glycerol 1 gram/1 each conventional release rectal suppository (clinical drug) |
| glycerol suppositorium a 2 g til børn |
Glycerol 2 g rectal suppository |
| glycerol suppositorium a 4 g til voksne |
Product containing precisely glycerol 4 gram/1 each conventional release rectal suppository (clinical drug) |
| Glycerol kinase deficiency |
Deficiency of glycerol kinase |
| glycerolkinasemangel - mikrodeletionssyndrom |
A rare chromosomal anomaly with characteristics of complex glycerol kinase deficiency, congenital adrenal hypoplasia, intellectual disability and/or Duchenne muscular dystrophy that usually affect males. The clinical features depend on the deletion size and the number and type of involved genes. |
| glyceryltrinitrat 0,4 % salve |
Product containing only glyceryl trinitrate (medicinal product) |
| glyceryltrinitrat 2 mg bukkaltablet med modificeret udløsning |
Glyceryl trinitrate 2 mg buccal tablet |
| glyceryltrinitrat 3 mg bukkaltablet med modificeret udløsning |
Product containing precisely glyceryl trinitrate 3 milligram/1 each conventional release buccal tablet (clinical drug) |
| glyceryltrinitrat 5 mg bukkaltablet med modificeret udløsning |
Glyceryl trinitrate 5 mg buccal tablet |
| allergi over for spray indeholdende glyceryltrinitrat |
Allergy to nitroglycerin |
| Glycosidase |
Glycosidase |
| glukosuri under graviditet med postnatal komplikation |
Pregnancy-related glycosuria |
| Glycosyltransferase |
Glycosyltransferase |
| gedemælk |
Goat's milk |
| Goldberg-Maxwell syndrome |
A disorder of sex development (DSD) characterized by the presence of female external genitalia, ambiguous genitalia or variable defects in virilization in a 46,XY individual with absent or partial responsiveness to age-appropriate levels of androgens. It comprises two clinical subgroups: complete AIS (CAIS) and partial AIS (PAIS). |
| Gomphocarpus physocarpus |
Asclepias physocarpus |
| Gomphrena physocarpus |
Asclepias physocarpus |
| Gonadal dysgenesis NOS |
Gonadal dysgenesis |
| Gonadal dysgenesis NOS |
Gonadal dysgenesis |
| Gonadotrophin levels NOS |
Pituitary gonadotropin measurement |
| Gonadotrophin levels NOS |
Pituitary gonadotropin measurement |
| gonorré med lokal komplikation |
Gonorrhea |
| Gorissennes tegn |
Jorissenne sign |
| Goura cristata cristata |
Goura cristata (organism) |
| Gout monitoring NOS |
Gout monitoring |
| Gout monitoring NOS |
Gout monitoring |
| Gout with other manifestation, NEC |
A disease caused by monosodium urate crystal deposition with any of the following clinical presentations (current or prior): gout flare, chronic gouty arthritis, or subcutaneous tophus. |
| Arthritis urica, ikke nærmere specificeret |
Gouty arthritis |
| nefropati ved urinsyregigt, ikke nærmere specificeret |
Chronic urate nephropathy (disorder) |
| Kronisk nefropati ved urinsyregigt, uspecificeret |
Chronic urate nephropathy (disorder) |
| grad af dysplasi i adenom ved proksimal resektionsrand |
Histologic grade of dysplasia at proximal surgical margin |
| Graderingsværdier |
Grades |
| Graft to organ NOC |
Grafting procedure |
| Graft to organ NOC NOS |
Grafting procedure |
| Grafting of bone, autogenous or bone bank |
Bone graft |
| Graft af slimhinde til hoved eller hals |
Reconstruction of head and/or neck with mucosal graft |
| Graft af nasolabiale lapper |
Reconstruction using nasolabial flap of skin (procedure) |
| Grafting of pedicle fascial flap |
Reconstruction using pedicle fascial flap (procedure) |
| Grafting of posterior tibial flap |
Reconstruction using posterior tibial artery fasciocutaneous flap |
| Grafting of tarsal or metatarsal |
Grafting of phalanges of foot |
FHIR